| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 4 | 5 | 5 | 6 | 6 | 12 | 12 | 21 | 60 | 77 | 37 | 39 |
| Expenses | 3 | 4 | 4 | 4 | 4 | 10 | 10 | 18 | 54 | 55 | 20 | 22 |
| EBITDA | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 7 | 22 | 17 | 18 |
| Operating Profit % | -10 % | 24 % | 29 % | 30 % | 29 % | 13 % | 13 % | 14 % | 9 % | 26 % | 39 % | 32 % |
| Depreciation | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Profit Before Tax | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 | 20 | 13 | 14 |
| Tax | 0 | 0 | 1 | 0 | 0 | 0 | -0 | 0 | 0 | 1 | 4 | 4 |
| Net Profit | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 4 | 19 | 10 | 10 |
| EPS in ₹ | 0.84 | 0.76 | 3.21 | 3.36 | 2.95 | 0.23 | 1.20 | 4.79 | 26.21 | 16.93 | 0.22 | 1.00 |
Shukra Pharmaceuticals
Shukra Pharmaceuticals
37.23
+0.73
(2.00%)
Key Fundamentals
Market Cap
1,598.30 Cr
EPS
0.22
PE Ratio
161.87
Dividend Yield
0.03 %
Industry
Healthcare 52 Week High
36.50
52 Week Low
5.75
PB Ratio
25.94
Debt to Equity
0.06
Sector
Pharmaceuticals Actual
Company News
View All News
Shukra Pharmaceuticals Receives Approval for Robotic Surgery Projects from Meril Healthcare
Oct 08, 2025
Oct 08, 2025Shukra Pharmaceuticals has gained approval from Meril Healthcare for robotic surgery projects with a timeline extending until March 2026. This development represents the company's strategic expansion into medical robotics and orthopedic technology sectors.
Shukra Pharmaceuticals has received approval from Wockhardt to manage and distribute its products throughout India. This partnership grants Shukra Pharmaceuticals distribution rights across the Indian market for Wockhardt's pharmaceutical products.
Shukra Pharma has received approval for a contract valued at 240.6 million rupees. The pharmaceutical company announced this contract approval, though specific details about the nature of the contract, duration, or contracting party were not disclosed.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,679.10 | #1 3,98,049.70 | 38.75 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 61.71 | |
6,621.50 | 1,75,222.50 | 76.19 | 9,712.00 | 18.67 | 2,191 | 26.74 | 72.60 | |
1,577.60 | 1,26,768.90 | 23.67 | 28,409.50 | 7.12 | 5,291 | 9.88 | 60.63 | |
3,584.30 | 1,19,599.80 | 60.49 | 11,539.40 | 6.99 | 1,911 | 19.91 | 53.74 | |
1,255.90 | 1,03,508.80 | #1 18.25 | 33,741.20 | 16.73 | 5,725 | 1.26 | 48.97 | |
2,476.60 | 1,01,344.60 | 53.48 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 47.04 | |
987.65 | 99,073.80 | 21.09 | 23,511.00 | 18.55 | 4,615 | 2.60 | 45.37 | |
1,940.00 | 89,121.90 | 23.79 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.82 | |
5,581.50 | 66,047.70 | 28.61 | 13,458.30 | 3.70 | 2,216 | 21.39 | 63.11 | |
1,101.00 | 64,254.10 | 19.04 | 32,345.60 | 9.43 | 3,484 | -10.24 | 50.87 |
Growth Rate
Revenue Growth
-52.45 %
Net Income Growth
-48.11 %
Cash Flow Change
252.31 %
ROE
-52.61 %
ROCE
-36.69 %
EBITDA Margin (Avg.)
60.33 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 |
| Fixed Assets | 10 | 10 | 10 | 14 | 16 | 17 | 18 | 18 | 20 | 20 | 19 |
| Current Assets | 7 | 6 | 7 | 8 | 11 | 15 | 16 | 16 | 53 | 56 | 65 |
| Capital Work in Progress | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 7 | 6 | 7 | 8 | 11 | 15 | 16 | 16 | 53 | 56 | 65 |
| Total Liabilities | 18 | 17 | 19 | 24 | 28 | 34 | 36 | 35 | 75 | 78 | 87 |
| Current Liabilities | 1 | 1 | 2 | 3 | 4 | 7 | 7 | 12 | 43 | 14 | 17 |
| Non Current Liabilities | 4 | 3 | 3 | 6 | 9 | 11 | 13 | 6 | 7 | 6 | 7 |
| Total Equity | 14 | 14 | 15 | 15 | 15 | 15 | 16 | 16 | 25 | 58 | 63 |
| Reserve & Surplus | 12 | 13 | 13 | 13 | 14 | 14 | 14 | 15 | 21 | 47 | 19 |
| Share Capital | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 4 | 11 | 44 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 1 | -1 | -1 | 0 | -0 | 0 | -0 | 4 | 6 | 2 |
| Investing Activities | 1 | -0 | -1 | -5 | -3 | -3 | -2 | -2 | -4 | -1 | -1 |
| Operating Activities | -2 | 3 | -0 | 1 | 0 | 1 | 1 | 8 | 3 | -5 | 8 |
| Financing Activities | 1 | -1 | 0 | 4 | 2 | 2 | 2 | -7 | 5 | 12 | -5 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
| Promoter | 49.17 % | 49.17 % | 49.17 % | 49.17 % | 49.17 % | 49.17 % | 49.17 % | 49.17 % | 50.90 % | 50.90 % | 50.90 % | 50.90 % | 50.96 % | 50.96 % | 50.96 % | 50.96 % | 50.96 % | 50.96 % | 50.96 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.80 % | 0.80 % | 0.80 % | 0.80 % | 0.80 % | 0.80 % | 0.80 % | 0.80 % | 0.11 % | 0.11 % | 0.11 % | 0.11 % | 0.11 % | 0.11 % | 0.11 % | 0.11 % | 0.11 % | 0.11 % | 0.11 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 33.02 % | 33.02 % | 32.90 % | 32.86 % | 32.83 % | 32.81 % | 33.00 % | 33.06 % | 29.14 % | 29.10 % | 29.11 % | 29.14 % | 28.94 % | 9.79 % | 9.19 % | 9.25 % | 9.41 % | 9.29 % | 28.69 % |
| Others | 17.01 % | 17.01 % | 17.14 % | 17.18 % | 17.21 % | 17.22 % | 17.04 % | 16.98 % | 19.85 % | 19.88 % | 19.88 % | 19.85 % | 19.99 % | 39.14 % | 39.73 % | 39.68 % | 39.51 % | 39.64 % | 20.24 % |
| No of Share Holders | 9,345 | 9,345 | 9,305 | 9,268 | 9,239 | 9,193 | 9,237 | 9,234 | 9,544 | 9,582 | 9,600 | 9,747 | 10,963 | 12,974 | 14,989 | 16,321 | 17,844 | 18,231 | 20,337 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.5 | 0.5 | 0.5 | 0.00 | 0.00 | 0.5 | 0.5 | 1 | 0.01 |
| Dividend Yield (%) | 0.00 | 156.25 | 263.16 | 208.33 | 0.00 | 0.00 | 42.74 | 6.13 | 4.58 | 0.03 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 01 Nov 2025 |  Extraordinary General Meeting | NA | 01 Nov 2025 | 34.45 | 37.23 |
| 19 Oct 2016 |  Change Of Name | NA | 19 Oct 2016 | 0.33 | 0.33 |
| 22 Sept 2022 |  Dividend | ₹ 0.50 /share | 22 Sept 2022 | 0.30 | 1.06 |
| 02 Feb 2023 |  Rights | 6:1 | 02 Feb 2023 | 0.84 | 1.37 |
| 16 Sept 2023 | Dividend | ₹ 0.50 /share | 15 Sept 2023 | 2.58 | 4.56 |
| 20 Apr 2024 |  Bonus | 3:1 | 19 Apr 2024 | 7.53 | 8.48 |
| 23 Aug 2024 | Extraordinary General Meeting | NA | 23 Aug 2024 | 9.01 | 6.14 |
| 24 Sept 2024 | Dividend | ₹ 1.00 /share | 23 Sept 2024 | 10.69 | 6.36 |
| 30 Sept 2024 |  Annual General Meeting | NA | 30 Sept 2024 | 6.39 | 6.75 |
| 14 Nov 2024 |  Quarterly Result Announcement | NA | 14 Nov 2024 | 6.93 | 6.49 |
| 14 Feb 2025 | Quarterly Result Announcement | NA | 14 Feb 2025 | 23.34 | 21.09 |
| 29 Jan 2025 |  Split | 1:10 | 21 Mar 2025 | 22.45 | 22.45 |
| 29 May 2025 | Quarterly Result Announcement | NA | 29 May 2025 | 13.98 | 13.27 |
| 13 Aug 2025 | Quarterly Result Announcement | NA | 13 Aug 2025 | 20.70 | 18.68 |
| 18 Sept 2025 | Dividend | ₹ 0.01 /share | 18 Sept 2025 | 13.26 | 30.04 |
| 30 Sept 2025 | Annual General Meeting | NA | 30 Sept 2025 | 26.22 | 35.16 |
Announcements
Announcement under Regulation 30 (LODR)-Newspaper Publication4 days ago
4 days agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Authorization Received From Meril Healthcare Private Limited For The Project Of ROBOTIC ASSISTED SURGERY SYSTEM FOR ORTHOPEDICS At Directorate General Armed Forces Medical Services And INHS Asvini Maharashtra.Oct 08, 2025
Oct 08, 2025Notice Of Extra Ordinary General Meeting Of Shukra Pharmaceuticals Limited To Be Held On Saturday November 01 2025.Oct 07, 2025
Oct 07, 2025Board Meeting Outcome for Revised Outcome Of The Meeting Of The Board Of Directors Held On Friday October 03 2025.Oct 04, 2025
Oct 04, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesOct 03, 2025
Oct 03, 2025Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On Friday October 03 2025.Oct 03, 2025
Oct 03, 2025Voting Result Along With Scrutinizer Report Of 32Nd Annual General Meeting (AGM) Of The Company Held On September 30 2025.Oct 03, 2025
Oct 03, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 30, 2025
Sep 30, 2025Closure of Trading WindowSep 29, 2025
Sep 29, 2025Board Meeting Intimation for Preferential Issue Of Warrants As Per Chapter V And In Accordance With Securities And Exchange Board Of India (Issue Of Capital And Disclosure Requirements) Regulations 2018 To Promoters Subject To Approval Of Shareholders.Sep 22, 2025
Sep 22, 2025Intimation Of Book Closure And Record Date Pursuant To Regulation 42 Of SEBI Listing Regulations For Annual General Meeting Of The Company.Sep 12, 2025
Sep 12, 2025Intimation Of Record Date For Final Dividend For Financial Year 2024-2025.Sep 12, 2025
Sep 12, 2025Corrigendum To The Notice Of 32ND Annual General Meeting And Annual Report (2024-25) Of The CompanySep 12, 2025
Sep 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 10, 2025
Sep 10, 2025Announcement Under Regulation 30 Of SEBI (LODR)- Strategic PAN India Distribution Tie-UpSep 10, 2025
Sep 10, 2025Reg. 34 (1) Annual Report.Sep 08, 2025
Sep 08, 2025Submission Of Notice Of 32Nd AGM Of The Companny.Sep 08, 2025
Sep 08, 2025Board Meeting Outcome for Outcome Of The Board Of Directors Of The Company.Sep 08, 2025
Sep 08, 2025Appointment Of Secretarial Auditor Of The Company Subject To Approval From The Members Of The Company.Aug 30, 2025
Aug 30, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sAug 30, 2025
Aug 30, 2025Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors Held On Today I.E. August 30 2025Aug 30, 2025
Aug 30, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderAug 28, 2025
Aug 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Un-Audited Financial Results Of The Company For The First Quarter Ended June 30 2025 Along With The Auditors Limited Review Reports In Accordance With The Provisions Of Regulation 33 Of The SEBI Listing Regulations.Aug 13, 2025
Aug 13, 2025Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On Wednesday August 13 2025.Aug 13, 2025
Aug 13, 2025Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On August 13 2025Jul 31, 2025
Jul 31, 2025Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsJul 26, 2025
Jul 26, 2025Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsJul 26, 2025
Jul 26, 2025Announcement under Regulation 30 (LODR)-Memorandum of Understanding /AgreementsJul 25, 2025
Jul 25, 2025Grant Of Distributorship RightsJul 21, 2025
Jul 21, 2025Strategic Expansion Through Opening Of Branch Offices In Mumbai Gurgaon(NCR) Bangalore And KolkataJul 09, 2025
Jul 09, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 04, 2025
Jul 04, 2025Closure of Trading WindowJun 28, 2025
Jun 28, 2025Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_OrderJun 27, 2025
Jun 27, 2025Corporate Action-Board approves DividendJun 04, 2025
Jun 04, 2025Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On Wednesday June 04 2025Jun 04, 2025
Jun 04, 2025Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On 04Th June 2025May 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
May 29, 2025Audited Financial Statement For The Quarter And Year Ended On March 31 2025May 29, 2025
May 29, 2025Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Held On Thursday May 29 2025May 29, 2025
May 29, 2025Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company Is Scheduled To Be Held On Thursday May 29 2025May 16, 2025
May 16, 2025Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 27, 2025
Apr 27, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 05, 2025
Apr 05, 2025Intimation Of Change In Secretarial Auditor Of The CompanyMar 29, 2025
Mar 29, 2025Outcome Of Independent Directors Meeting Dated March 26 2025.Mar 26, 2025
Mar 26, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Corporate Action-Updates on intimation of Sub division / Stock SplitMar 20, 2025
Mar 20, 2025Corporate Action-updates on Outcome of Sub division / Stock SplitMar 18, 2025
Mar 18, 2025Technical Indicators
RSI(14)
Neutral 77.15
ATR(14)
Less Volatile 0.68
STOCH(9,6)
Overbought 82.23
STOCH RSI(14)
Neutral 49.40
MACD(12,26)
Bearish -0.04
ADX(14)
Strong Trend 48.21
UO(9)
Bearish 86.74
ROC(12)
Uptrend And Accelerating 3.82
WillR(14)
Overbought 0.00
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
